Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA

References

• Verspoor FG, van der Geest IC, Vegt E, Veth RP, van der Graaf WT, Schreuder HW. Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol. 9(10), 1515–1531 (2013).
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F. WHO Classification of tumours of soft tissue and bone. IARC, Lyon, 2003, 305–310 (2013).
   Google Scholar
• Tyler WK, Vidal AF, Williams RJ, Healey JH. Pigmented villonodular synovitis. J. Am. Acad. Orthop. Surg. 14(6), 376–385 (2006).
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Tong S, McQuarrie K et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin. Ther. 38(4), 778–793 (2016 Apr).
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Maki RG et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur. J. Cancer 51(2), 210–217 (2015).
   PubMed Web of Science ®Google Scholar
• Verschoor A, Bovee J, van de Sande M, Gelderblom H ( Eds). Incidence and demographics of giant cell containing tumors in the Netherlands: a nationwide pathology database study. Presented at: Paper presented at Annual Meeting of the Connective Tissue Oncology Society. Salt Lake City, UT, USA, 4–7 November 2015.
   Google Scholar
• Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine (Baltimore). 59(3), 223–238 (1980).
   PubMed Web of Science ®Google Scholar
• Verspoor FG, Zee AA, Hannink G, van der Geest IC, Veth RP, Schreuder HW. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. Rheumatology 53(11), 2063–2070 (2014).
   PubMed Web of Science ®Google Scholar
• Xie GP, Jiang N, Liang CX et al. Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases. PLOS ONE 10(3), e0121451 (2015).
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Verspoor FGM, Verschoor AJ et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta. Orthop. 88(6), 688–694 (2017).
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Hoek DM, Bovée JVMG, van de Sande MAJ, Szuhai K. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Histopathology 74(2), 332–340 (2019).
   PubMed Web of Science ®Google Scholar
• de St Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour, localized type. In: WHO classification of tumours of soft tissue and bone (4th Edition). Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F ( Eds). WHO Press, Geneva, Switzerland, 5, 100–101 (2013).
   Google Scholar
• Ushijima M, Hashimoto H, Tsuneyoshi M, Enjoji M. Giant cell tumor of the tendon sheath (nodular tenosynovitis). A study of 207 cases to compare the large joint group with the common digit group. Cancer 57(4), 875–884 (1986).
   PubMed Web of Science ®Google Scholar
• Chiari C, Pirich C, Brannath W, Kotz R, Trieb K. What affects the recurrence and clinical outcome of pigmented villonodular synovitis? Clin. Orthop. Relat. Res. 450, 172–178 (2006).
   PubMed Web of Science ®Google Scholar
• Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop. Traumatol. Surg. Res. 103(1S), S91–S97 (2017).
   PubMedGoogle Scholar
• Brahmi M, Cassier P, Dufresne A et al. Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). PLOS ONE 15(5), e0233046 (2020).
   PubMed Web of Science ®Google Scholar
• Verspoor FGM, Mastboom MJL, Hannink G et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Sci. Rep. 9(1), 14551 (2019).
   PubMed Web of Science ®Google Scholar
• Tap WD, Wainberg ZA, Anthony SP et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373(5), 428–437 (2015).
   PubMed Web of Science ®Google Scholar
• Staals EL, Ferrari S, Donati DM, Palmerini E. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur. J. Cancer 63, 34–40 (2016).
   PubMed Web of Science ®Google Scholar
• Tap WD, Gelderblom H, Palmerini E et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN), a randomised Phase III trial. Lancet 394(10197), 478–487 (2019).
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion Phase I study. Lancet Oncol. 16(8), 949–956 (2015).
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Cropet C, Chevreau C et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 19(5), 639–648 (2018).
   PubMed Web of Science ®Google Scholar
• Bernthal NM, Spierenburg G, Healey JH et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J. Rare Dis. 16(1), 191 (2021).
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Inc. TURALIO (pexidartinib). [ package insert] (2020). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2020/211810s003lbl.pdf
   Google Scholar
• Tap W. ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 16(25), 1875–1878 (2020).
   PubMed Web of Science ®Google Scholar
• Robert M, Farese H, Miossec P. Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front. Immunol. 13, 820046 (2022).
   PubMed Web of Science ®Google Scholar
• Lee J-C, Huang H-Y. Soft tissue special issue: giant cell-rich lesions of the head and neck region. Head Neck Pathol. 14(1), 97–108 (2020).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 1.2022) (2022). www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf
   Google Scholar
• Ober NS, Grubmuller J, Farrell M et al. System and method for generating de-identified health care data. In: Google Patents. (2004). https://patents.google.com/patent/US7865376B2/en
   Google Scholar
• Ober NS, Grubmuller J, Farrell M et al. System and method for generating de-identified health care data. In: Google Patents. (2008). https://patents.google.com/patent/US7376677B2/en
   Google Scholar
• Zubeldia K, Romney GW. Anonymously linking a plurality of data records. In: Google Patents. (2002). https://patents.google.com/patent/US6397224B1/en
   Google Scholar
• Shenolikar R, Liu S, Shah A, Tse J, Cao Y, Near A. Real-world treatment patterns of metastatic non-small-cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Med. 12(1), 159–169 (2023).
   PubMed Web of Science ®Google Scholar
• Burton TM, Ye X, Parker ED, Bancroft T, Healey J. Burden of illness associated with tenosynovial giant cell tumors. Clin. Ther. 40(4), 593–602.e591 (2018).
   PubMed Web of Science ®Google Scholar
• Lin F, Ionescu-Ittu R, Pivneva I et al. The economic burden of tenosynovial giant cell tumors among employed workforce in the United States. J. Occup. Environ. Med. 63(4), e197–e202 (2021).
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173(6), 676–682 (2011).
   PubMed Web of Science ®Google Scholar
• Statistical Analysis System, SAS. SAS Release 9.4 for windows. SAS Institute Inc., Cary, NC, USA (2013).
   Google Scholar
• Ehrenstein V, Andersen SL, Qazi I et al. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. a registry-based cohort study in Denmark. J. Rheumatol. 44(10), 1476–1483 (2017).
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau, Population Division. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2010 to July 1, 2019 (NC-EST2019-AGESEX) (2022). www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html
   Google Scholar
• Lin F, Kwong WJ, Shi S, Pivneva I, Wu EQ, Abraham JA. Surgical treatment patterns, healthcare resource utilization, and economic burden in patients with tenosynovial giant cell tumor who underwent joint surgery in the United States. J. Health Econ. Outcomes Res. 9(1), 68–74 (2022).
   PubMedGoogle Scholar
• Stephan SR, Shallop B, Lackman R, Kim TWB, Mulcahey MK. Pigmented villonodular synovitis: a comprehensive review and proposed treatment algorithm. JBJS Rev. 4(7), e3 (2016).
   PubMedGoogle Scholar
• Fotiadis E, Papadopoulos A, Svarnas T, Akritopoulos P, Sachinis NP, Chalidis BE. Giant cell tumour of tendon sheath of the digits. A systematic review. Hand (N Y). 6(3), 244–249 (2011).
   PubMedGoogle Scholar
• van der Heijden L, Gibbons CL, Hassan AB et al. A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal. J. Surg. Oncol. 107(4), 433–445 (2013).
   PubMed Web of Science ®Google Scholar
• Sharma V, Cheng EY. Outcomes after excision of pigmented villonodular synovitis of the knee. Clin. Orthop. Relat. Res. 467(11), 2852–2858 (2009).
   PubMed Web of Science ®Google Scholar
• González Della Valle A, Piccaluga F, Potter HG, Salvati EA, Pusso R. Pigmented villonodular synovitis of the hip: 2- to 23-year followup study. Clin. Orthop. Relat. Res. 388(7), 187–199 (2001).
   Google Scholar
• Mastboom MJL, Palmerini E, Verspoor FGM et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 20(6), 877–886 (2019).
   PubMed Web of Science ®Google Scholar
• Lin F, Qian C, Kwong J. Treatment patterns of tenosynovial giant cell tumor among commercially insured patients: a retrospective claims analysis. J. Clin. Oncol. 36(suppl. 15), e18737 (2018).
   Web of Science ®Google Scholar
• Mastboom MJ, Planje R, van de Sande MA. The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. Interact. J. Med. Res. 7(1), e4 (2018).
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Aranda-Reneo I, Rodríguez-Sánchez B et al. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet J. Rare Dis. 16(1), 294 (2021).
   PubMed Web of Science ®Google Scholar
• Vaynrub A, Healey JH, Tap W, Vaynrub M. Pexidartinib in the management of advanced tenosynovial giant cell tumor: focus on patient selection and special considerations. Onco Targets Ther. 15, 53–66 (2022).
   PubMed Web of Science ®Google Scholar
• Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology 57(7 Suppl. 57), vii54–vii58 (2018).
   PubMedGoogle Scholar
• Gelderblom H, Wagner AJ, Tap WD et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer 127(6), 884–893 (2021).
   PubMed Web of Science ®Google Scholar
• Novartis. GLEEVEC (imatinib mesylate). [ package insert] (2016). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf
   Google Scholar
• Novartis. TASIGNA (nilotinib). [ package insert] (2017). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s024lbl.pdf
   Google Scholar
• Bayer. NEXAVAR (sorafenib). [ package insert] (2018). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
   Google Scholar
• Pfizer. SUTENT (sunitinib malate). [ package insert] (2017). Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2017/021938s033lbl.pdf
   Google Scholar
• Brahmi M, Cassier P, Dufresne A et al. Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). PLOS ONE 15(5), e0233046 (2020).
   PubMed Web of Science ®Google Scholar
• Palmerini E, Healey JH, Bernthal NM et al. 2-Year Observational Analysis of Patient-Reported Outcomes and Treatment Strategies from the Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry. Oncologist (2022) ( unpublished).
   Web of Science ®Google Scholar
• Takeuchi A, Endo M, Kawai A et al. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: the REALIZE study. Front Oncol. 12, 900010 (2022).
   PubMed Web of Science ®Google Scholar